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Abstract 
Background: Noroviruses (NoVs) are a major cause of childhood gastroenteritis and foodborne diseases worldwide. 
Lack of appropriate animal models or cell‑based culture systems makes the development and evaluation of NoV‑spe‑
cific vaccines a daunting task. VP1 is the major capsid protein of the NoVs that acts as a binding motif to human histo‑
blood group antigens (HBGAs) through its protruding 2 (P2) domain and can serve as a protective antigen candidate 
for vaccine development.
Methods: Recombinantly produced NoV specific P domain (Pd) vaccine was inoculated into groups of mice either 
alone or in conjugation with mucosal adjuvant FlaB, the flagellar protein from Vibrio vulnificus. Antigen specific 
humoral and cell mediated immune responses were assessed by enzyme linked immunosorbent assay (ELISA) or fluo‑
rescent activated cell sorting (FACS). A comparative analysis of various routes of vaccination viz. intranasal, sublingual 
and subcutaneous, was also done.
Results: In this study, we show that a recombinant Pd‑vaccine administered through intranasal route induced 
a robust TH2‑dependent humoral immune response and that the combination of vaccine with FlaB significantly 
enhanced the antibody response. Interestingly, FlaB induced a mixed TH1/TH2 type of immune response with a 
significant induction of IgG1 as well as IgG2a antibodies. FlaB also induced strong IgA responses in serum and feces. 
FlaB mediated antibody responses were toll like receptor 5 (TLR5) dependent, since the FlaB adjuvanticity was lost in 
TLR5−/− mice. Further, though the Pd‑vaccine by itself failed to induce a cell mediated immune response, the Pd‑FlaB 
combination stimulated a robust CD4+IFNγ+ and CD8+IFNγ+ T cell response in spleen and mesenteric lymph nodes. 
We also compared the adjuvant effects of FlaB with that of alum and complete Freund’s adjuvant (CFA). We found that 
subcutaneously inoculated FlaB induced more significant levels of IgG and IgA in both serum and feces compared to 
alum or CFA in respective samples.
Conclusion: We validate the use of TLR5 agonist as a strong mucosal adjuvant that would facilitate the development 
of NoV specific vaccines for humans and veterinary use. This study also highlights the importance of route of immuni‑
zation in inducing the appropriate immune responses in mucosal compartments.
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Background
Human noroviruses (NoVs) are the leading cause of 
childhood gastroenteritis and foodborne diseases world-
wide [1]. Human NoVs, belonging to the genus Norovirus 
within the family Caliciviridae, are a group of small, posi-
tive sense, single-stranded, non-enveloped viruses hav-
ing 7–8 kb RNA genome with four open reading frames 
(ORFs) [2, 3]. Major and minor capsid proteins VP1 and 
VP2 are encoded by the ORF2 and 3, respectively [4]. 
ORF1 encodes the nonstructural protein and ORF4 has 
been described recently to play a significant role in the 
murine NoV pathogenesis [3, 5]. The absence of efficient 
and reproducible cell culture systems and small-animal 
models has hindered the studies concerning the patho-
genesis and molecular mechanisms of NoV life cycle as 
well as the development of effective vaccines and thera-
peutic agents [5, 6].
Virus-like particle (VLP)-vaccines have been devel-
oped and approved for the prevention of hepatitis B virus 
(HBV) [7, 8] and human papillomavirus (HPV) [9, 10] 
infections. The capsid proteins of NoVs have been char-
acterized to generate VLPs (comprised of major struc-
tural protein VP1), P particle (comprised of P domain 
with –C terminal CDCRGDCFC peptide) and P domain 
(Pd also called P dimer) (Fig. 1a) [11–13]. The structural 
variants of NoV VLPs have been shown to be presented 
efficiently by dendritic cells (DCs) and elicit efficient 
serum IgG antibody responses [11]. Given NoVs are 
pathogens of gastrointestinal tract that cause pathology 
primarily in the small intestine, effective vaccines should 
induce significant secretory antibodies in gastrointestinal 
tract to effectively control viral invasion and shedding in 
feces, and restrict the human-to-human spread. Subunit 
protein vaccines (e.g. Pd-vaccine) are poor inducers of 
humoral immune responses, in particular secretory anti-
body responses [14]. In this context, the use of adjuvants 
potentiating immune responses in the mucosal immune 
compartments will significantly boost the vaccine effi-
cacy [15]. One particular group of immune-enhancers 
that can be exploited as mucosal adjuvants is toll like 
receptors (TLRs) [16]. TLRs are pattern recognition 
receptors (PRRs) that specifically recognize their cognate 
agonist(s), also known as pathogen associated molecu-
lar patterns (PAMPs). The TLR agonists include bacte-
rial products, CpG motifs, virus-specific nucleotides (i.e. 
dsRNA) and imidazoquinoline compounds [17]. In our 
previous studies we have shown that FlaB, a flagellin pro-
tein from Vibrio vulnificus and an agonist of TLR5, is a 
potent adjuvant for mucosally administered vaccines [18]. 
In the present study, we evaluated the potential of FlaB 
coadministration along with the recombinant Pd anti-
gen in enhancing the antigen-specific protective immune 
responses. We report that the intranasal immunization 
of mice with Pd+FlaB mixture vaccine induced a potent 
antibody and cell mediated immune response in both 
systemic and mucosal compartments. We also com-
pared the immune efficacy after vaccine administration 
through sublingual route. Additionally, we evaluated the 
advantages of FlaB over known vaccine adjuvants such as 
alum and complete Freund’s adjuvant (CFA).
Methods
Antigen preparation and LPS removal
Norovirus VA387 strain (GII.4) P dimer-specific DNA 
fragments were cloned between NdeI-KpnI restric-
tion sites and expressed in pET30a+ vector (Novagen) 
as a His-tagged protein. All proteins were expressed 
in Escherichia coli BL21 with an induction by 0.1  mM 
isopropyl-β-d-thiogalactopyranoside (IPTG) at 37  °C 
overnight. Bacterial pellets were dissolved in 8  M urea 
followed by sonication (2 s on to 3 s off cycles/5 min at 
30  % of max. voltage) on ice. Following centrifugation 
(8000 rpm/15 min/4 °C), protein from cell free superna-
tant was purified by affinity purification using Ni–NTA 
Agarose beads (Qiagen) as per manufacturer’s instruc-
tions. Protein was dialyzed extensively against sterile 
phosphate buffered saline (PBS) followed by LPS removal 
by treatment with TritonX-114 (Sigma). Traces of Tri-
ton X-114 were removed by treatment with Bio-Beads™ 
SM-2 (Bio Rad) as per manufacturer’s instructions. For 
the production of FlaB protein, a 1.5-kb fragment con-
taining the open reading frame of V. vulnificus flaB was 
cloned into pTYB12-yielding pCMM250 (New England 
Biolabs). Recombinant FlaB was purified as previously 
reported [18]. Finally all proteins were suspended in ster-
ile PBS at appropriate concentrations.
Animals, vaccination and sampling
Specific pathogen free (SPF) female Balb/c WT mice 
were purchased from Charles River Inc. while TLR5−/− 
mice on Balb/c background were bred and maintained 
under SPF conditions at the animal facility of Clinical 
Vaccine R&D Center of Chonnam National University. 
The mouse study protocol was approved by the Com-
mittee on Animal Welfare at Chonnam National Univer-
sity Medical School. Mice were immunized at an age of 
6–7  weeks. The animals were housed in a temperature- 
and light-controlled environment and had free access 
to food and water. Various antigen combinations were 
used at equimolar concentrations. Vaccination groups 
included (1) P dimer (Pd), (2) Pd +  FlaB, (3) FlaB, and 
(4) PBS. All antigens were inoculated through intranasal 
(i.n.) or sublingual (s.l.) routes into anaesthetized ani-
mals. Final volume for i.n. as well as s.l. vaccination was 
10  μl/animal. In a separate experiment, groups of five 
mice were immunized subcutaneously with either alum 
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precipitated Pd [19], Pd-CFA mixture, or Pd+FlaB mix-
ture. In all the adjuvant groups, concentration of Pd anti-
gen inoculated into mice was kept constant at 0.1  μM/
dose. Animals were immunized thrice. In the CFA group, 
the first vaccination was done with CFA + Pd followed by 
two immunizations at one-week interval with incomplete 
Freund’s adjuvant along with Pd. In all immunization 
groups, before each respective vaccination, mouse serum 
Fig. 1 Antigen construction and expression. a Nomenclature and location of various domains of NoV VLPs. b 3D structure of VP1 encoded by ORF2 
of human NoV (GII.4) (GenBank accession# AY038600.3) and of the P domain (Pd) cloned into bacterial vector system (for details see ‘‘methods’’). 
Numbers in (a, b) represent the amino acid numbers. c The Western blot of the bacterially expressed and purified Pd protein reacted with anti‑Pd 
hyper‑immune serum raised in mice. The recombinant Pd protein was separated by the native PAGE
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as well as feces were collected and processed for antibody 
determination. One week after the third immunization, 
final blood and feces samples from mice were procured. 
Feces samples were made into a 20 % solution (w/v) in ice 
cold PBS containing 1 mM phenylmethylsulfonyl fluoride 
(PMSF). All clarified serum and feces samples were kept 
at −80 °C until used.
NoV specific enzyme linked immunosorbent assay (ELISA)
Antibody titers in serum and feces samples from indi-
vidual animals were estimated by ELISA using Pd as the 
coating antigen. Samples were serially diluted in a dilu-
tion buffer (PBS  +  1  % BSA  +  0.05  %Tween20). Anti-
mouse IgG, IgA, IgG1 and IgG2a specific Horse radish 
peroxidase (HRP) conjugated secondary antibodies 
(Southern Biotech) were used at a dilution of 1:2000. 
Finally HRP-specific optical reactions were developed 
using the BD OptEIA™ (BD Biosciences, San Diego, 
USA) for 15 min followed by stopping the reaction with 
2 N H2SO4. Reactions were read at OD450 using Spectra 
Max 190 microplate reader (Molecular Devices). The cut-
off value was decided as per formula: (Mean OD450 of 
negative control wells) + 3 (standard deviation of OD450 
of negative control wells). Log2 of the reciprocal of high-
est dilution showing OD450 value equivalent to or higher 
than the cut off value was taken as the antibody titer.
Tissue processing, lymphocyte isolation, cell stimulation 
assay and flow cytometry
Spleen, mesenteric lymph nodes (MLNs) and Payer’s 
patches (PPs) were harvested from animals in various 
immunization groups 2  weeks after the final immuni-
zation and kept in ice-cold cell culture medium until 
processed. All tissues were mashed through 40  μm cell 
strainer (BD Falcon). In case of spleen, lymphocytes 
were purified by density centrifugation using the Lym-
phoprep™ (Life Technologies) followed by red cells lysis 
by ACK lysis buffer (Lonza Inc., USA) for 5 min at room 
temperature (RT). Cells were finally suspended in the cell 
culture medium (RPMI1640 + 10 % FBS + 1 % Penicil-
lin/Streptomycin) and kept on ice until used. For in vitro 
stimulation assays, 1 × 106 cells in duplicate were plated 
in separate flat-bottom 96 wells and stimulated with 1 μg 
of Pd protein for 12 h. Golgistop™ (BD Biosciences, San 
Diego, CA) was added for the entire duration of incu-
bation. Post-incubation cells were fixed and permeabi-
lized using the Cytofix/Cytoperm kit (BD Biosciences) 
in accordance with the manufacturer’s instructions. The 
anti-mouse antibodies used for intracellular and sur-
face staining (eBioscience or BD Pharmingen™) were 
CD4-APC (clone GK1.5), CD8-APC (clone 53–6.7) and 
IFNγ-PE (clone XMG1.2). Stained cells were acquired on 
FACS Accuri (BD Biosciences). Data analysis was per-
formed using the FlowJo software (TreeStar, San Carlos, 
CA).
Statistical analysis
Statistical analysis of data was done using the GraphPad 
Prism software ver. 6.0 or Microsoft Excel as appropriate. 
P < 0.05 was taken as significant.
Results
Cloning and expression of NoV P dimer (Pd)
Norovirus specific P dimer (Pd) containing two P1 
domains and one central P2 domain (Fig.  1a) was 
expressed as a recombinant protein in Escherichia coli 
BL21. Homology modelling [20] suggested that though 
the complete viral protein had slightly dispersed struc-
ture (Fig.  1b), the P domain from ORF2 encompassing 
amino acid 222–539 had globular structure that would 
tend to have a compact three dimensional (3D) organi-
zation (Fig.  1b). This observation was substantiated by 
the non-denaturing native polyacrylamide gel electro-
phoresis (PAGE) of the cloned protein that showed that 
most of Pd protein remained in the stacking gel (Fig. 1c). 
The Western blot analysis from sodium dodecyl sulphate 
(SDS)-PAGE showed that the recombinantly produced 
protein had a major single monomeric unit of 37  kDa 
while minor fractions of ca. 80  kDa and over 120  kDa, 
representing dimer and multimeric proteins respectively, 
were also present (Fig. 1b).
FlaB enhances Pd‑specific antibody responses in a 
TLR5‑dependent manner
In order to estimate the immunogenicity of P dimers 
expressed in bacterial system, mice were immunized 
through i.n. or s.l. route using Pd antigen alone or in 
combination with FlaB (Pd + FlaB). FlaB and PBS were 
included as negative controls. For the estimation of the 
kinetics of anti-Pd specific immune responses, serum 
and feces samples, taken before each vaccination and 
1  week after the final vaccination, were assayed by 
ELISA. After vaccination with Pd, we noted a steady 
increase in serum IgG levels that peaked only after third 
immunization. On the other hand, the immunization 
with Pd + FlaB induced a strong immune response even 
after the first immunization that resulted in significantly 
high serum IgG levels (Fig. 2a, b). Nonetheless, the anti-
body responses appeared to be boosted significantly by 
repeated immunizations even in the Pd only immunized 
groups. Particularly, immunization with Pd resulted in 
significantly higher IgG responses in serum of immu-
nized animals through both i.n. (14.5  ±  2.16, log2 
titer ± SD; P = 0.002) as well as s.l. routes (13 ± 2.08; 
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Fig. 2 Induction of humoral immune response post‑immunization. a, b The kinetics of appearance of IgG after immunization with Pd or Pd + FlaB 
given through intranasal (i.n.) and sublingual (s.l.) routes respectively. c The comparative serum‑IgG antibody titers after final vaccination. d, e The 
kinetics of appearance of serum IgA antibodies after i.n. and s.l. inoculations of various antigens. The legends for (a), (b), (d), (e) are in (g). f The 
serum‑IgA levels 1 week after final immunization. g The kinetics of appearance of feces‑IgA after s.l. immunization. (h) The final feces‑IgA titers 
1 week after final vaccination. i–k The respective serum IgG, serum IgA and fecal IgA antibody titers from TLR5 −/− mice. Statistical differences were 
compared by the Student’s t test for unpaired means. *P < 0.05, **P < 0.01, ***P < 0.001, nsnot significant. The error bars represent the standard error 
of mean (SEM)
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P  =  0.003) (Fig.  2c). However, presence of FlaB along 
with Pd (Pd + FlaB) very significantly enhanced the anti-
gen-specific (18 ± 1.08; P < 0.0001) immune responses 
when given through i.n. route (Fig.  2c). On the other 
hand, the immune responses induced after s.l. immu-
nization using Pd  +  FlaB (15.875  ±  0.478) were also 
significantly higher than the negative control groups 
(P  <  0.05) but were significantly less than the respec-
tive immunization done through i.n. route (Fig.  2a–c). 
The IgA antibody responses in the serum showed sim-
ilar patterns with those of IgG antibodies (Fig.  2d and 
f ). The i.n. immunization using Pd + FlaB induced the 
most potent serum-IgA response (18.25  ±  1.258) that 
was significantly higher than that after immunization 
with Pd alone (12.25 ±  0.645; P =  0.0005) (Fig.  2d, f ). 
The s.l. immunization route manifested similar results 
(Fig.  2e) though the titers were slightly lower than the 
i.n route (Fig. 2d). However, highest IgA levels in feces 
were induced upon vaccination with Pd + FlaB through 
s.l. route (13  ±  2.273) (Fig.  2g) that was significantly 
higher than any other groups irrespective of immuni-
zation routes (Fig.  2h). No significant IgG levels were 
detected in the feces in any immunization groups (data 
not shown). As expected, the enhancement of Pd spe-
cific antibody titers by FlaB was mediated through TLR5 
since significant increases in antigen-specific antibody 
titers were not observed in TLR5−/− mice (Fig.  2i–k). 
Though the levels of fecal-IgA in TLR5−/− mice induced 
upon Pd  +  FlaB immunization tended to be slightly 
higher than Pd alone, but the difference did not reach 
a statistical difference (Fig. 2k). These data indicate that 
FlaB significantly induced mucosal and systemic IgA 
and IgG responses in TLR5 dependent manner.
FlaB polarizes a mixed TH1/TH2 type humoral immune 
response against NoV Pd‑vaccine
We further delineated the type and magnitude of immune 
response induced upon vaccination with various antigen 
combinations. Pd given through i.n. route induced a sig-
nificant level of IgG1 (P < 0.001) (Fig. 3a) as well as IgG2a 
(P < 0.05) (Fig. 3b) antibody titers. On the other hand, Pd 
given through s.l. route induced significant titers of IgG1 
(P = 0.005) (Fig. 3a) but not IgG2a (P = 0.475) (Fig. 3b). 
Evidently Pd alone induced TH2 skewed humoral immune 
response as the levels of IgG1 antibodies induced through 
i.n. or s.l. route were significantly higher than the titers 
of IgG2a induced through respective routes (P  <  0.01). 
Incorporation of FlaB into vaccine formulation as a mix-
ture (Pd  +  FlaB) significantly enhanced the respective 
antibody titers in both immunization routes (P  <  0.01) 
(Fig. 3a, b). More importantly, Pd + FlaB mixture skewed 
the Pd induced humoral immune response from TH2 
type to a mixed TH1/TH2 type as a higher increase in 
IgG2a antibody titers was observed after vaccination 
with Pd + FlaB (P = 0.0004) (Fig. 3b). These results indi-
cate that the nature of immune responses to Pd has been 
changed by the action of mucosal adjuvant FlaB. These 
results also indicate that appropriate immune responses 
can be directed to specific immune compartments by 
altering the antigen formulation with specific adjuvant or 
route used for immunization.
FlaB potentiates Pd‑specific cell mediated immune 
responses in systemic and local immune compartments
Next we examined the cell mediated immunity gener-
ated in response to different antigen formulation and 
immunization routes. For this, 2 weeks after the third 
Fig. 3 Induction of Th1/Th2 skewed immune responses post‑vaccination. a Shows the serum‑IgG1 levels while b shows the serum‑IgG2a antibody 
levels 1 week after final vaccination of animals through i.n. or s.l. routes. Statistical differences were compared by the Student’s t test for unpaired 
means. *P < 0.05, **P < 0.01, ***P < 0.001, nsnot significant. The error bars represent the standard error of mean (SEM)
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immunization, single cell suspensions from spleen, 
mesenteric lymph nodes (MLNs) and Peyer’s patches 
(PPs) were incubated with the purified Pd and Brefel-
din A, after which cell activation and cytokine pro-
duction were estimated by FACS analysis. Notably, 
while the percentages of IFNγ secreting lymphocytes 
were negligible in PBS group, a significant induc-
tion of CD8+IFNγ+ T lymphocytes was observed in 
spleen and MLNs after i.n. immunization with the 
Pd vaccine that was further significantly enhanced in 
Pd  +  FlaB group (Fig.  4a, c). Though the Pd vaccine 
by itself failed to induce a significant CD8+IFNγ+ T 
cell response in PPs, combination with FlaB resulted 
in enhanced response in PPs (Fig.  4b). On the con-
trary, in s.l. immunized animals, the levels of IFNγ 
induced in CD8+ cells after Pd or Pd  +  FlaB immu-
nization remained insignificantly different from each 
other in all the three organs tested (Fig.  4a–c). Very 
interestingly, the levels of CD4+IFNγ+ T cells induced 
in all three organs after i.n. immunization with Pd 
or Pd  +  FlaB were not significantly different from 
each other though were higher than the PBS group 
(Fig. 4a–c). When compared across the immunization 
routes, in Pd + FlaB immunized animals, CD8+IFNγ+ 
(Fig. 4d) and CD4+IFNγ+ T (Fig. 4e) cell responses in 
spleen and MLN of i.n. immunized animals was sig-
nificantly higher than those observed after s.l. immu-
nization while such significant difference in the two 
T cell responses was not observed in PPs between i.n. 
and s.l. immunization routes. These data indicate that 
Pd vaccine given through i.n. route induces stronger 
CD8+IFNγ+ and CD4+IFNγ+ cell responses in spleen 
and MLN but not in PPs while combination with FlaB 
resulted in significant enhancement of respective 
responses (Fig.  4a–c). It is noteworthy that the CD8+ 
and CD4+ cell populations observed here may be con-
stituted of other non-lymphocytic cells that may also 
be positive for these markers. Nonetheless, proportion 
of such cells in the tissues studied remain substantially 
low. Hence, these data clearly indicate that the i.n. 
route is better for the induction of IFNγ producing Pd-
specific immune cells in the spleen and MLN than the 
s.l. route. But s.l. immunization appeared as efficient 
as the i.n. route in inducing IFNγ producing CD8+ and 
CD4+ cells in PPs.
FlaB induces similar systemic immune responses compared 
to alum and CFA, while inducing significantly higher 
secretory antibody responses in feces
We compared the adjuvant effects of TLR5 agonist 
FlaB with already very well documented vaccine adju-
vant alum and CFA. For objective comparison, same 
dose of antigen mixed with respective adjuvant was 
inoculated subcutaneously three times. One week after 
the final immunization, feces and serum samples were 
procured for antibody estimation by ELISA. We found 
that, compared to alum, FlaB and CFA induced signifi-
cantly higher levels of IgG in serum (Fig. 5a) (P < 0.01). 
Upon further evaluation of subclasses of IgG antibodies 
induced by various adjuvants, we found that FlaB as well 
as CFA tended to induce high levels of mixed IgG1 and 
IgG2a antibody responses, whereas alum induced high 
levels of IgG1 (Fig.  5b). Interestingly, the levels of IgG 
induced by FlaB +  Pd in feces were significantly higher 
than the other two adjuvants (Fig. 5c) (P < 0.01). It was 
interesting to note that subcutaneous immunization with 
FlaB +  Pd induced high fecal IgG levels (Fig.  5c), while 
such antibodies were not detected upon giving FlaB + Pd 
through i.n. or s.l. routes (data not shown). Besides, we 
also found that FlaB induced high levels of IgA in serum 
that were significantly higher than those in CFA and 
alum groups (Fig. 5d) (P < 0.05). Moreover, the levels of 
fecal IgA induced by FlaB were significantly higher than 
that induced by alum and CFA (Fig. 5e) (P < 0.01). Hence, 
these results indicate that bacterial flagellin acts as a 
strong adjuvant that induces high levels of both secretory 
as well as virus binding antibodies in serum and feces 
even when administered systemically.
Discussion
In the present study, we have shown that NoV specific 
P domain (Pd) recombinant vaccine, produced in E. coli 
system, effectively induced substantial humoral immu-
nity in mice. The combination of Pd with the mucosal 
adjuvant FlaB [18] enhanced the humoral immune 
responses in a TLR5 dependent manner and also induced 
significant cell mediated immunity in systemic and local 
immune compartments. In general, the route of vacci-
nation is critical for successful immunization outcomes 
against specific infections [21]. Most parenterally admin-
istered vaccines fail to induce local mucosal immune 
responses that act as a first line of defense against patho-
gens that invade through gastrointestinal surfaces. An 
important feature of present study is the information 
on the kinetics of antibody induction after vaccination 
through intranasal and sublingual routes. In agreement 
with previous reports, the immunization through intra-
nasal as well as sublingual routes seems to induce con-
siderable systemic as well as local antibody responses 
[22]. However, the Pd vaccine given through i.n. route 
induced higher IgG antibody titers after two immuniza-
tions, which were significantly higher than the antibody 
titers induced after s.l. immunization. On the other hand, 
secretory IgA antibody levels in feces were higher after 
the s.l. immunization compared with the i.n. route. The 
difference in vaccine efficacy given through two routes 
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Fig. 4 Induction of cell mediated immune responses in various immune compartments after immunization with Pd and Pd + FlaB through various 
routes. a–c Representative FACS micrograph showing percent of CD8+IFNg+ and CD4+IFNg+ cell numbers in mesenteric lymph nodes (MLN), 
payer’s patches (PP) and spleen after i.n. or s.l. immunization, as depicted in the picture. d, e The statistical analysis of cell percentages of IFNγ secret‑
ing CD8+ (d) and CD4+ (e) induced in spleen, MLN and PPs after Pd + FlaB immunization through i.n. and s.l. routes. Statistical differences were 
calculated by student’s t test for unpaired means. *P < 0.05, **P < 0.01, ***P < 0.001, nsnot significant. The error bars represent the standard error of 
mean (SEM)
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can be attributed to the initial tissue types associated 
with antigen capture. Nasal associated lymphoid tissue 
(NALT) is a secondary lymphoid organ with organized 
cell clusters while the sublingual mucosa is a non-organ-
ized type II mucosal tissue with dispersed immune cells 
that lack an organized cell clustering. However, combina-
tion of Pd with the mucosal adjuvant FlaB seems to over-
come this hurdle and induce high antibody titers after 
two immunizations that might be due to the induction of 
immune responses mediated through the epithelial cells 
of buccal mucosa [23] or indirect activation of innate 
immune cells [24].
Direct effects of flagellin on B cell activation and anti-
body production [25] have been refuted variously [26], 
while stimulatory effects of flagellin on dendritic cells 
and T cells have been reported to promote a dramatic 
Fig. 5 Comparison of various adjuvants for antibody induction. a, b The kinetics of appearance of IgG and IgG subclasses after immunization with 
Pd‑vaccine mixed with various adjuvants and given through subcutaneous routes. c Comparative fecal IgG levels induced after final vaccination. d, 
e The respective serum and fecal IgA levels induced after vaccination with Pd combined with different adjuvants. P values were calculated by the 
paired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. The error bars represent the standard error of mean (SEM)
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increase in T cell dependent antibody production [27]. 
The humoral responses enhanced by FlaB were charac-
terized by high levels of IgG1 and IgG2a that are required 
to provide complete protection against the targeted path-
ogen [26]. Like many other subunit vaccines, the Pd vac-
cine administered through either mucosal route (i.n. or 
s.l.) induced a TH2 skewed immune response resulting in 
higher IgG1 over IgG2a titers. However, addition of FlaB 
to the formulation resulted in the induction of TH1 type 
immune response providing a mixed TH1/TH2 antibody 
response. We envisage that the multifunctional immune 
response generated after immune-potentiation by FlaB 
will provide superior efficacy in preventing NoV infec-
tions in human and animals. Moreover, we have previ-
ously shown that FlaB is a very effective and safe mucosal 
adjuvant as after i.n. immunization it does not accumu-
late in olfactory tissues and the central nervous system 
[18, 28].
In a few NoV vaccine studies done in humans [29] and 
chimpanzees [30] the correlates of protection indicate 
that both antibody and cell mediated immune responses 
are necessary to clear NoVs. In particular, in a mouse 
model, CD4 and CD8 T cells were required for clearance 
of virus from the intestine [31, 32]. Immune responses in 
mucosal tissues are governed by the nature of the anti-
gen, the type of APCs involved, and the local microen-
vironment. With most types of non-adjuvanted peptide/
protein antigens, the ‘default’ immune response seems 
to be the TH2 type response that may cause active sup-
pression of systemic immunity [14]. However, antigens 
and adjuvants, including most PAMPs sensed by mucosal 
APCs as ‘danger signals’ (e.g. TLR ligands), favor the 
development of stronger and broader immune responses 
engaging both the humoral-secretory and cellular immu-
nity effector arms. In the present study we found that 
P domain based vaccine, given alone, did not induce a 
substantial cell mediated immunity. However, as shown 
previously for other antigens [33], combination of Pd vac-
cine with flagellin resulted in induction of significantly 
higher IFNγ secreting CMI. Interestingly, i.n. immuniza-
tion using Pd+FlaB tended to induce much higher levels 
of IFNγ secreting CD8+ and CD4+ lymphocytes than 
the same antigen combination given through s.l. route. 
Though there is a consensus regarding flagellin’s ability 
to induce CD4+ T cell-mediated immune responses, the 
TLR5-dependent CD8+ immune response is less defined. 
Data in the present study support previous reports that 
testified the significant activation of CD8+ lymphocytes 
through TLR5 signaling [34, 35]. However, there are 
studies that did not note the induction of cytotoxic T cell 
responses after immunization with flagellin adjuvant [36] 
highlighting the fact that the nature and characteristics 
of co-administered antigen, and route of immunization 
should determine the type and magnitude of the result-
ing immune response. Hence, every candidate antigen 
should be tested with adjuvant rather than predicting 
effects based upon published results.
Alum is the most common adjuvant used in approved 
prophylactic vaccines [37]. However, the propensity of 
alum based adjuvants to induce a TH2-skewed immune 
response and their inability to induce cell mediated 
immune responses [38], limits wider application against 
diseases where TH1 or cytotoxic T cell responses are 
critical for immune protection. Hence, we compared 
the adjuvant effects of FlaB with alum and CFA. CFA 
is an experimental adjuvant composed of oil-in-water 
emulsion incorporated with killed mycobacteria and is 
not recommended for human usage because of severe 
adverse inflammatory reactions at the site of inocula-
tion [39]. Nonetheless, it is one of the strongest induc-
ers of antibody and cell mediated immune responses. 
We found that FlaB induced high levels of serum IgG 
that were comparable to IgG levels induced by CFA but 
were significantly higher than that induced by alum. We 
further found that the levels of IgG2a induced after alum 
vaccination were significantly less than that induced by 
FlaB or CFA, though the levels of IgG1 were comparable 
among three groups. Moreover, induction of high levels 
of secretory IgA antibodies in feces of FlaB immunized 
animals but not in other two groups established the supe-
riority of FlaB as an adjuvant given through mucosal (i.n. 
or s.l.) or non-parenteral routes. Taken together, these 
results indicate the importance of use of an appropriate 
adjuvant such as FlaB for induction of protective immune 
reactions in local settings. These results, in conjugation 
with our previously published reports, further support 
the superiority of FlaB as a mucosal adjuvant in induc-
ing the antigen specific antibody as well as cell mediated 
immune reactions in the local mucosal settings.
Conclusions
We show that NoV specific immune responses could 
be significantly fortified by the use of TLR5 agonist 
when given through mucosal route. The data in the pre-
sent manuscript also conclusively demonstrate that for 
induction of relevant immune responses in appropriate 
immune compartments, route of immunization is a deci-
sive factor. These results pave a way for the development 
of a relevant vaccine for human as well as veterinary use, 
in which NoV induced diarrhea and foodborne infections 
are a major cause of distress and financial loss.
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